Commercial interests appear to be influencing evidence standards for multi-cancer early detection tests

Dario Trapani, Medical Oncologist at European Institute of Oncology, shared a post by Benjamin Mazer, Assistant Professor of Pathology at Johns Hopkins University, on X:

“Commercials determinants of health are now being investigated and tacked based on a systematic strategy.

Cancer screening is now a big part of this problem.

See the recent WHO/Europe report from the NCD to learn more. ”

Quoting Benjamin Mazer‘s post:

“Commercial interests appear to be influencing evidence standards for multi-cancer early detection tests.”

Multicancer Early Detection Tests — Keeping a High Bar for Evidence of Benefit | NEJM

Authors: Hilary A. Robbins

Source: Dario Trapani/X and Benjamin Mazer/X